Abstract | BACKGROUND: METHODS AND RESULTS: Four patients with AS, aged from 20 to 40 years at the beginning of treatment, were enrolled in our study. All patients reported disruption to their daily lives from the myoclonus movement. They experienced mild to moderate improvement with the starting dose of 2 mg. The dose was increased to 4 mg in one patient to achieve sufficient efficacy, while two had their dose reduced to 1 mg due to dizziness or possible exacerbation of myoclonus. The last patient continued to take the starting dose. Follow-up over 16-20 months revealed a significant reduction in the severity of nonepileptic myoclonus in all patients. CONCLUSION: Our study suggests that PER could be one of the promising drugs for nonepileptic myoclonus in AS.
|
Authors | Osamu Kawano, Kiyoshi Egawa, Hideaki Shiraishi |
Journal | Brain & development
(Brain Dev)
Vol. 42
Issue 5
Pg. 389-392
(May 2020)
ISSN: 1872-7131 [Electronic] Netherlands |
PMID | 32164978
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2020 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Anticonvulsants
- Nitriles
- Pyridones
- perampanel
|
Topics |
- Adult
- Angelman Syndrome
(complications)
- Anticonvulsants
(therapeutic use)
- Female
- Humans
- Male
- Myoclonus
(drug therapy, genetics)
- Nitriles
- Pyridones
(therapeutic use)
- Young Adult
|